“Time poor” single mothers come surprisingly close in the number of hours they spend caring for their children compared to married mothers, and the difference is explained almost entirely by socio-economic factors and the kind of jobs they hold, say University of Maryland sociologists in a new study. The researchers conclude public policy focuses too
Full Post: Study looks at amount of time single mothers are able to give their children
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares’ needle-free injection devices with its human growth hormone (hGH), Zomacton.
Ferring has been notified recently that the mutual recognition process for European member states has been positively concluded for the Zomacton 10 mg formulation and the Antares’ needle-free injection device (Zomajet Vision X) and consumables. Following an initial product launch in France, Ferring expects to launch in the other key European markets in 2009. The Zomacton 4 mg formulation with the Zomajet 2 Vision needle-free device and consumables was previously approved in Europe and is currently being marketed.
In addition, the Therapeutic Goods Administration, Australia’s regulatory agency for drugs and devices, has recently approved applications filed by Ferring for the Antares Zomajet 2 Vision and Vision X needle-free injection devices, and their associated consumables, to be used with Zomacton in both the 4 mg and 10 mg formulations.
Paul Wotton, Ph.D., President and Chief Executive Officer of Antares, commented, We are pleased that Ferring continues to expand into new markets and is introducing the Vision X device for use with their Zomacton 10 mg product. The combination of the higher strength formulation with Antares’ proprietary needle-free system will continue the focus for both companies of enhancing patient compliance and convenience with self administration of hGH.
http://www.antarespharma.com/
--------------------------------------------------------------------------------------------
Related Posts:
Reports from the United States that authorities there have approved a handgun designed for those crippled by conditions such as arthritis and muscular dystrophy have given rise to confusion and debate. Apparently the single-shot ‘Palm Pistol’ had been reportedly approved by the U.S. Food and Drug Administration (FDA) as a Class 1 Medical Device, meant
Full Post: When is a gun a medical device?
Abbott and Advanced Medical Optics (AMO) have announced a definitive agreement for Abbott to acquire AMO for $22 per share in cash, for a total transaction value of approximately $2.8 billion, inclusive of estimated net debt at the time of closing. Based in Santa Ana, Calif., AMO is a global leader in ophthalmic care, comprised
Full Post: Abbott to acquire Advanced Medical Optics
Covidien has announced that it is launching a new and improved Magellan Safety Hypodermic Needle. The development of the new design, which gives clinicians more control and smoother activation of the safety shield, reflects Covidien’s continued commitment to improving healthcare worker safety. “We are transitioning to the new and improved Magellan Safety Needle technology as
Full Post: Launch of new safety hypodermic needle
Watson Pharmaceuticals, Inc. has announced that its subsidiary, Watson Laboratories, Inc., has received final approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets (XL) in the 150 mg strength. Bupropion Hydrochloride Extended-Release Tablets is the generic equivalent to GlaxoSmithKline’s Wellbutrin XL(R) product,
Full Post: Watson Pharmaceuticals receives FDA approval for generic Wellbutrin XL
Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval
Full Post: FDA advisory committee to dscuss PMA for Genzyme’s Synvisc-One --------------------------------------------------------------------------------------------
